絞り込み

16506

広告

「vildagliptin」の検索結果

914件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.

Cardiovascular effects of sitagliptin --an anti-diabetes medicine.

Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea.

Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance.

Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes.

The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration.

Ten Years of Vildagliptin.

Drug fever and acute inflammation via hypercytokinemia triggered by dipeptidyl peptidase-4 inhibitor vildagliptin.

Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, Improves Trabecular Bone Mineral Density and Microstructure in Obese, Insulin-Resistant, Pre-diabetic Rats.

A Randomized Controlled Trial to Compare the Effects of Sulphonylurea Gliclazide MR (Modified Release) and the DPP-4 Inhibitor Vildagliptin on Glycemic Variability and Control Measured by Continuous Glucose Monitoring (CGM) in Brazilian Women with Type 2 Diabetes.

Reduced salivary amylase activity in metabolic syndrome patients with obesity could be improved by treatment with a dipeptidyl peptidase IV inhibitor.

Vildagliptin/Pioglitazone Combination Improved The Overall Glycemic Control In Type I Diabetic Rats.

Different Glucagon Effects During DPP-4 Inhibition versus SGLT-2 Inhibition in Metformin-Treated Type 2 Diabetes Subjects.

Anti-diabetic phenolic compounds of black carrot (Daucus carota subspecies sativus var. atrorubens Alef.) inhibit enzymes of glucose metabolism: An in silico and in vitro validation.

Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.

Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain.

The safety of gliptins : updated data in 2018.

Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes.

Vildagliptin significantly increases the risk of bullous pemphigoid: A Finnish nationwide registry study.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります